Use of Aflibercept 8 mg for the Treatment of Diabetic Macular Edema in Italy: A Cost-Minimisation Analysis Based on an Indirect Treatment Comparison
Aflibercept 8 mg may be the most advantageous anti-VEGF option for reducing treatment burden in Italian patients with DME, benefiting healthcare providers, clinics, and the healthcare system. Aflibercept 8 mg offers comparable efficacy and safety to other anti-VEGF therapies, with fewer injections and potentially lower overall costs.
Authors
- Monica Zurria
- Paolo Angelo Cortesi (ORCID: https://orcid.org/0000-0001-5241-4473)
- Mario Fazzi D’Orsi
- Izabella Lunk
- Francesco Bandello
- Mohammed Alshaikheid
- Marwa Mezghani
Institutions
- Newcastle College (GB)
- Tunisia Private University (TN)
- Bayer (Switzerland) (CH)
- Bayer (Italy) (IT)
- IRCCS Istituto Auxologico Italiano (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- University of Milano-Bicocca (IT)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2026-03-28
- DOI
- https://doi.org/10.1007/s12325-026-03553-z
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00